Nektar Therapeutics
NASDAQ:NKTR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.42
1.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Nektar Therapeutics
Nektar Therapeutics
Other Long-Term Assets
Nektar Therapeutics
Other Long-Term Assets Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nektar Therapeutics
NASDAQ:NKTR
|
Other Long-Term Assets
$4.3m
|
CAGR 3-Years
143%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-18%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$6.2B
|
CAGR 3-Years
38%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$18.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
27%
|
CAGR 10-Years
15%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$13.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$12.5B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
See Also
What is Nektar Therapeutics's Other Long-Term Assets?
Other Long-Term Assets
4.3m
USD
Based on the financial report for Jun 30, 2024, Nektar Therapeutics's Other Long-Term Assets amounts to 4.3m USD.
What is Nektar Therapeutics's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-18%
Over the last year, the Other Long-Term Assets growth was 154%. The average annual Other Long-Term Assets growth rates for Nektar Therapeutics have been 143% over the past three years , 12% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet
